IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

tba

Filed:

tba

1st Inventor:

Kaneyoshi KATO

For:

Melanin Concentrating Hormone Antagonist

Atty. Dkt. No.

2648 US0P

Art Unit:

tba

Examiner: tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

BOX Patent Application Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference is herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: March / ,:

(847) 383-3372

(847) 383-3391

(047) 303-3312

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Haif Day Road Lincolnshire, IL 60069 USA

Application No.:	tts.	Art Unit tha				
Filed:	ttpa.	Examine: tha				
I dinventor:	K_KATO	Allowed:				
For:	Melanin Concentrating Hormone Antagonist	Betch:				
Atty Dkt. No.	2648 US0P	Paper No.:				
1. This Posterad a 2. Transmitted Leg 3. Copy of Reque 4. Specification - 5. Copy of Terms 6. Copy of Interms 7. Copy of Interms 8. Copy of Interms 9. Copy of Writte 10. First Preliminat 11. Information 12 12. Assignment (2 13. Declaration 120	rested to kindly acknowledge receipt of the following Certificate of Express Mailing (2 pages) and Certificate of Express Mailing (2 pages) X2 years from of the International Application PCT/IP00/06375, (10tal 352 pages, including Claims 1-38 (pages 336-352), A PCT/IB/301, 304, 308 and 332 (6 pages) at page of the International Application as published (WO-internal Preliminary Examination Report (8 pages) an Opinion (PCT/IPEA/408) (8 pages) in Opinion (PCT/IPEA/408) (8 pages) no Opinion (PCT/IPEA/408) (8 pages) yearnedment (19 pages) with Form PTO 1449 (1 page) pages) and Recontation Cover Sheet (1 page X Z) 1 Power of Attorney (5 pages)	(Form PCL/RO/101)(4 pages) abstract (1 page) and Sequence Listing (11 pages) 01/21577) (1 page)				

10/088771 107886'd PCT/PTO 9 MAR 2002

Respectfully rubmitted 3/19/02 For Customer No. 23,115 Express Mail Label No. EL 91649:2917US By Mark Claso, Fall, JD - Reg. No. 37,293

Application No.: Filed: 1" inventor: Por:	tha K. KATO Melanin Concentrating Hormone Antagonist	Art Unit: the Examiner: tha Allowed: Eatch: Peoper No.:
1. This Postard at 2. Transmittal Let 3. Copy of Reque 4. Specification - 5. Copy of Forms 6. Copy of Intern 8. Copy of Intern 9. Copy of Intern 9. Copy of Writh 10. First Prelimin 11. Information 2. Assignment C 13. Declaration at Respectfully submit	ested to kindly acknowledge receipt of the following Certificate of Express Mailing (2 pages) ter for Filing under 35 USC 371 (2 pages X 2) stem of the International Application PCT//PCO/0637: total 352 pages, including Claims 1-38 (pages 336-352) PCT////////////////////////////////////	5, (Farm PCT/RO/101)(4 pages) , Abstract (1 page) and Soquence Listing (11 pages (O 01/21577) (1 page)

13:04

Page 1 of 1					***				
FORM PTO	1449 (mod	lified)		ГАТ	TY DOCKET NO	١٠	SERIAL NO	· · · · · · · · · · · · · · · · · · ·	
				2648 USOP		tha			
U.S. DEPARTMENT OF COMMERCE			-	2040 0001		100			
PATENT AND TRADEMARK OFFICE			1				•		
LIST OF	LIST OF REFERENCES CITED BY APPLICANT(S)		1			j .			
Į.	(Use ser	veral sheets if necessary)						•	
Date Submitte	d to PTO	<u>:</u>	<u> </u>				}	•	
1				AP.	PLICANT:KATO	, K			•
				<u> </u>					
			FILING DATE:		GROUP: tba				
THE SECRETARIAN PROPERTY.	TO WATERWAY WERE THE SECOND CASES AND SECOND COMMENTS OF THE SECOND		toa		Examiner tha				
Management of the second				PANT.	Name of the last				
							> 6		
COLOR COLOR DE LA COLOR DE	A SANCE SHANKER	THE PERSONAL PROPERTY.	MARCH 1002					A SECTION AS	
		· · · · ·				1	1		,
V. (1994)						Side relation to the second			derformente
مده	AI	WO 95/32967	12/7/1995			NAME OF TAXABLE PARTY.			
111					WIPO	· .			
,	A2	WO 98/38156	9/3/1998		WIPO	 		- 	ļ. <u> </u>
		_	3.5.7.550		"#"				
	A3	WO 99/01127	1/14/1999		WIPO	_		-	
] """		1		
	A4	DE 2108185	9/7/1972	_	EP			Yes - Abstract	
		<u> </u>			[only	
Į.	A.5	DE 2448257	4/22/1976		EP			Yes - Abstract	
			1				1	only	
. 1	A6	DE 2502588	7/29/1976		EP			Yes - ABCT	
	_						ì	enly	,
1	A7	EP 0533266	3/24/1993		EP				
		 						·	
j	A8	WO 96/35671	11/14/1996		WIPO		,		
-		<u> </u>							
- 1	A9	EP 0920864	6/9/1999	ŀ	EP				
_	1470	TVO DOD FORM					_	_	
	A10	WO 98/15274	4/16/1998	ſ	WIPO		}	1 ' 1	1
	A11	WP 99/52857	10/21/2000	-	TITTO	·	- 		
Y	1	***************************************	10/21/1999	- }	WIPO		1	1	
					OLD WATER				o de la companional
	WE B								THE RESERVE
118	A12	Mewshaw, et al. "New	Generation D	Opami	nergic Agents. 1	. Discove	ry of a Novel	Scaffold Which Embra	cos the D
MF		Agonist Pharmacophor	e. Structure –	-Activi	ity Relationships of	of a Series	of 2-(Arring	nethyl)chromans" JOU	RNAL OF
	<u> </u>	Agonist Pharmacophore. Structure —Activity Relationships of a Series of 2-(Aminomethyl)chromans. JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)							
- 1	A13	Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D. Antagonists/5-HT.							sts/5-HT _{IA}
	1	Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY							MISTRY
+	ATA	42:3342-55(1999)							
- 1	A14	Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-							
1	A15	247(21 March 1996)							
A15 Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)									1
XAMINER:	MINER: DATE CONSIDERED: - 4/21/200<								
···	IV.				- ~~omeren	·	4/21/	3005)	H